![Katie Peng](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Katie Peng
Directeur/Bestuurslid bij
SCHOLAR ROCK HOLDING CORPORATION
Vermogen: 2 M $ op 31-05-2026
Profiel
Ms. Katie Peng is an Independent Director at Scholar Rock Holding Corp., an Independent Director at Adicet Bio, Inc. and a Chief Commercial Officer at Denali Therapeutics, Inc. She is on the Board of Directors at Scholar Rock Holding Corp., Adicet Bio, Inc. and California Life Sciences Association.
Ms. Peng was previously employed as a General Manager by Roche Products Ltd. (Taiwan), a General Manager by Roche Singapore Pte Ltd., and a Senior Vice President & Head-OMNI Business Unit by Genentech, Inc. She received her undergraduate degree from the University of California, Berkeley and an MBA from Kelley School of Business.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 04-06-2026 | 39.747 ( 0,03% ) | 2 M $ | 31-05-2026 | |
| 21-06-2026 | 368 ( 0% ) | 3 426 $ | 31-05-2026 |
Actieve functies van Katie Peng
| Bedrijven | Functie | Begin |
|---|---|---|
| DENALI THERAPEUTICS INC. | Corporate Officer/Principal | 27-09-2021 |
| ADICET BIO, INC. | Directeur/Bestuurslid | 10-07-2023 |
| SCHOLAR ROCK HOLDING CORPORATION | Directeur/Bestuurslid | 15-02-2024 |
California Life Sciences Association
 California Life Sciences Association Miscellaneous Commercial ServicesCommercial Services Acts as a trade association which represents the life sciences industry of California | Directeur/Bestuurslid | - |
Eerdere bekende functies van Katie Peng
| Bedrijven | Functie | Einde |
|---|---|---|
Roche Products Ltd. (Taiwan) | Algemeen Directeur | 01-03-2017 |
Roche Singapore Pte Ltd.
 Roche Singapore Pte Ltd. Pharmaceuticals: MajorHealth Technology Develops new medicines and diagnostics solutions | Algemeen Directeur | 01-03-2015 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | - |
Opleiding van Katie Peng
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
16
Eerstegraads connecties
9
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 9 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roche Singapore Pte Ltd.
Roche Singapore Pte Ltd. Pharmaceuticals: MajorHealth Technology Develops new medicines and diagnostics solutions | Health Technology |
Roche Products Ltd. (Taiwan) | |
Kelley School of Business
 Kelley School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Denali Therapeutics, Inc.
 Denali Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for neurodegenerative diseases | Health Technology |
Scholar Rock Holding Corp.
 Scholar Rock Holding Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that focused on the discovery, development and delivery medicines for neuromuscular, cardiometabolic disorders, cancer, fibrosis and iron-restricted anemia | Health Technology |
California Life Sciences Association
California Life Sciences Association Miscellaneous Commercial ServicesCommercial Services Acts as a trade association which represents the life sciences industry of California | Commercial Services |
Adicet Bio, Inc.
 Adicet Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on the development of cell immunotherapies | Health Technology |
Kies MarketScreener 
